Abdulrahman Katib: Factor XI Inhibitors as the Next Frontier in the Thrombosis Treatment Landscape
Abdulrahman Katib, Internal Medicine and Adult Thrombosis Consultant at King Faisal Specialist Hospital and Research Center, shared on LinkedIn:
“Factor XI inhibitors are quickly becoming one of the most intensely studied drug classes in thrombosis medicine today.
What makes them so exciting is the possibility of achieving meaningful antithrombotic protection while preserving hemostasis — something we have been striving for in anticoagulation for decades.
That said, true clinical efficacy still needs to be firmly established in some of our highest-risk populations, particularly cancer-associated thrombosis (CAT), where thrombosis biology and bleeding risk coexist in a very delicate balance.
On a personal level, I was truly privileged to be part of the MAGNOLIA and ASTER trials.
Being involved in research at this stage — before results are known — is a unique experience. It reminds you that every future guideline, every future practice change, starts with patients, investigators, and teams working together to answer difficult clinical questions.
I am genuinely looking forward to seeing the final publications and understanding where Factor XI inhibition will ultimately position itself in our thrombosis treatment landscape.”
More posts about Abdulrahman Katib.
-
Sep 25, 2026, 14:12Managing Breakthrough Bleeds in Hemophilia – National Bleeding Disorders Foundation
-
Sep 25, 2026, 13:50Alejandro González Veliz: Beyond the Golden Hour in Stroke Care
-
Sep 25, 2026, 13:32Gevorg Yaghjyan: Low Drug Levels, Higher Cardiovascular Risk in Lupus
-
Sep 25, 2026, 12:53Bastu Odoka: What Happened to Blood Donation?
-
Sep 25, 2026, 12:43Thomas Dayspring: Reshaping the Biology of Atherosclerotic Plaques with New Therapies
-
Sep 25, 2026, 12:14Garima Sharma: Community Clinical Linkages for Better Postpartum Cardiovascular Care
-
Sep 25, 2026, 10:49Shefina S: From Presenting to Hosting at TRANSCON 2026
-
Sep 25, 2026, 10:37Michelle Leona Cecil: Hemophilia Advocacy and the Power of Community
-
Sep 25, 2026, 10:13Michael Baria: Platelet Concentration and PRP Outcomes in Partial Rotator Cuff Tears